We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-9.38%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$28M
Cap. Flow
+$68.7M
Cap. Flow %
18.16%
Top 10 Hldgs %
65.17%
Holding
31
New
7
Increased
16
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$17.6M
2
INCY icon
Incyte
INCY
+$17.1M
3
ARVN icon
Arvinas
ARVN
+$15.2M
4
UTHR icon
United Therapeutics
UTHR
+$14.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.3M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$23.4M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$15.6M
4
ARGX icon
argenx
ARGX
+$14.7M
5
INSM icon
Insmed
INSM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$37.7M 9.98%
321,621
+103,463
+47% +$12M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$33.5M 8.86%
966,827
+186,347
+24% +$5.57M
ARVN icon
3
Arvinas
ARVN
$518M
$33.1M 8.74%
491,333
+222,814
+83% +$15.2M
LEGN icon
4
Legend Biotech
LEGN
$4.3B
$30.2M 7.99%
831,728
+445,761
+115% +$17.6M
SRRA
5
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$24.7M 6.54%
771,314
+296,369
+62% +$8.5M
VRDN icon
6
Viridian Therapeutics
VRDN
$2.13B
$23.2M 6.14%
1,256,051
+47,000
+4% +$903K
INCY icon
7
Incyte
INCY
$23.5B
$18.6M 4.92%
+234,419
New +$17.1M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$15.3M 4.05%
910,416
+94,835
+12% +$1.4M
IOVA icon
9
Iovance Biotherapeutics
IOVA
$2.23B
$15.1M 4%
907,428
+63,423
+8% +$981K
IMCR icon
10
Immunocore
IMCR
$1.78B
$14.9M 3.95%
499,190
+364,941
+272% +$9.21M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$14.3M 3.79%
+136,243
New +$13.3M
UTHR icon
12
United Therapeutics
UTHR
$26.3B
$13.6M 3.59%
+75,635
New +$14.4M
ZNTL icon
13
Zentalis Pharmaceuticals
ZNTL
$308M
$13.3M 3.51%
287,577
-12,857
-4% -$694K
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.84B
$12.2M 3.22%
701,356
+248,265
+55% +$4.18M
CCCC icon
15
C4 Therapeutics
CCCC
$376M
$12.1M 3.2%
499,496
+240,750
+93% +$5.85M
OYST
16
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$11.5M 3.04%
987,698
+683,460
+225% +$8.14M
PRTA icon
17
Prothena Corp
PRTA
$458M
$9.8M 2.59%
+267,946
New +$9.66M
KYMR icon
18
Kymera Therapeutics
KYMR
$9.1B
$9.61M 2.54%
227,034
+101,176
+80% +$4.27M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.09M 2.14%
98,383
-161,732
-62% -$16.5M
MRUS
20
DELISTED
Merus
MRUS
$6.6M 1.75%
+249,738
New +$6.69M
VOR icon
21
Vor Biopharma
VOR
$1.04B
$5.4M 1.43%
44,720
+13,253
+42% +$2.26M
ESPR
22
DELISTED
Esperion Therapeutics
ESPR
$5.37M 1.42%
1,157,246
+317,989
+38% +$1.36M
FULC icon
23
Fulcrum Therapeutics
FULC
$248M
$5.04M 1.33%
+212,961
New +$3.01M
ALPN
24
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.02M 0.8%
+336,229
New +$2.91M
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$1.82M 0.48%
783,445
+238,057
+44% +$811K
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Paradigm Biocapital Advisors held 31 positions worth $378M, up 8% from $350M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Paradigm Biocapital Advisors deployed $68.7M of net new capital in Q1 2022, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Incyte: 234,419 shares worth $18.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $16.5M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2022 buy was Incyte: 234,419 shares worth $18.6M.
  • Paradigm Biocapital Advisors added most to Legend Biotech in Q1 2022, an estimated $17.6M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $16.5M.
  • Paradigm Biocapital Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $23.4M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $378M portfolio in Q1 2022.
  • Paradigm Biocapital Advisors opened 7 new positions and closed 6 in Q1 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 8% quarter-over-quarter to $378M.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2022, filed 16 May 2022.